Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Long-Term Outcomes of Arteriovenous Fistulas with Unassisted versus Assisted Maturation: A Retrospective National Hemodialysis Cohort Study.

Lee T, Qian JZ, Zhang Y, Thamer M, Allon M.

J Am Soc Nephrol. 2019 Nov;30(11):2209-2218. doi: 10.1681/ASN.2019030318. Epub 2019 Oct 14.

PMID:
31611240
2.

A comparison of predialysis estimated glomerular filtration rate in the US, Canada, France, Australia, and the UK between 2005 and 2015.

Rosansky SJ, Thamer M, Caskey F, Couchoud C, McDonald SP, Moist L.

Kidney Int. 2019 May;95(5):1273. doi: 10.1016/j.kint.2019.02.008. No abstract available.

PMID:
31010481
3.

Gender Disparities in Vascular Access Surgical Outcomes in Elderly Hemodialysis Patients.

Lee T, Qian J, Thamer M, Allon M.

Am J Nephrol. 2019;49(1):11-19. doi: 10.1159/000495261. Epub 2018 Dec 13.

PMID:
30544112
4.

Dialysis in Older Adults: Is Later Start the Preferred Approach?

Rosansky SJ, Thamer M, Crews DC.

Am J Kidney Dis. 2019 Feb;73(2):285-287. doi: 10.1053/j.ajkd.2018.09.001. Epub 2018 Oct 25. No abstract available.

PMID:
30482580
5.

Detecting weak signals from interfaces by high accuracy phase-resolved SFG spectroscopy.

Thämer M, Campen RK, Wolf M.

Phys Chem Chem Phys. 2018 Oct 17;20(40):25875-25882. doi: 10.1039/c8cp04239j.

PMID:
30288514
6.

Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?

Jain MK, Thamer M, Therapondos G, Shiffman ML, Kshirsagar O, Clark C, Wong RJ.

Hepatology. 2019 Jan;69(1):51-63. doi: 10.1002/hep.30171. Epub 2018 Dec 18.

PMID:
30019478
7.

Tradeoffs in Vascular Access Selection in Elderly Patients Initiating Hemodialysis With a Catheter.

Lee T, Qian J, Thamer M, Allon M.

Am J Kidney Dis. 2018 Oct;72(4):509-518. doi: 10.1053/j.ajkd.2018.03.023. Epub 2018 May 18.

8.

Medicare Costs Associated With Arteriovenous Fistulas Among US Hemodialysis Patients.

Thamer M, Lee TC, Wasse H, Glickman MH, Qian J, Gottlieb D, Toner S, Pflederer TA.

Am J Kidney Dis. 2018 Jul;72(1):10-18. doi: 10.1053/j.ajkd.2018.01.034. Epub 2018 Mar 28.

9.

Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment.

Wong RJ, Jain MK, Therapondos G, Shiffman ML, Kshirsagar O, Clark C, Thamer M.

Am J Gastroenterol. 2018 Sep;113(9):1329-1338. doi: 10.1038/s41395-018-0033-8. Epub 2018 Mar 9.

PMID:
29523864
10.

Impact of the End Stage Renal Disease Prospective Payment System on the Use of Peritoneal Dialysis.

Zhang Q, Thamer M, Kshirsagar O, Zhang Y.

Kidney Int Rep. 2016 Dec 20;2(3):350-358. doi: 10.1016/j.ekir.2016.12.004. eCollection 2017 May.

11.

Vascular Access Type and Clinical Outcomes among Elderly Patients on Hemodialysis.

Lee T, Thamer M, Zhang Q, Zhang Y, Allon M.

Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1823-1830. doi: 10.2215/CJN.01410217. Epub 2017 Aug 10.

12.

Comparing the Effectiveness of Dynamic Treatment Strategies Using Electronic Health Records: An Application of the Parametric g-Formula to Anemia Management Strategies.

Zhang Y, Young JG, Thamer M, Hernán MA.

Health Serv Res. 2018 Jun;53(3):1900-1918. doi: 10.1111/1475-6773.12718. Epub 2017 May 30.

13.

Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.

Noxon V, Knopf KB, Norris LB, Chen B, Yang YT, Qureshi ZP, Hrushesky W, Lebby AA, Schooley B, Hikmet N, Dickson M, Thamer M, Cotter D, Yarnold PR, Bennett CL.

J Oncol Pract. 2017 Jun;13(6):e562-e573. doi: 10.1200/JOP.2016.019364. Epub 2017 May 15.

14.

Hydrophobic Water Probed Experimentally at the Gold Electrode/Aqueous Interface.

Tong Y, Lapointe F, Thämer M, Wolf M, Campen RK.

Angew Chem Int Ed Engl. 2017 Apr 3;56(15):4211-4214. doi: 10.1002/anie.201612183. Epub 2017 Mar 16.

PMID:
28300334
15.

Anharmonic exciton dynamics and energy dissipation in liquid water from two-dimensional infrared spectroscopy.

De Marco L, Fournier JA, Thämer M, Carpenter W, Tokmakoff A.

J Chem Phys. 2016 Sep 7;145(9):094501. doi: 10.1063/1.4961752.

PMID:
27608998
16.

Association of Peritonitis with Hemodialysis Catheter Dependence after Modality Switch.

Lee T, Thamer M, Zhang Y, Zhang Q, Allon M.

Clin J Am Soc Nephrol. 2016 Nov 7;11(11):1999-2004. Epub 2016 Aug 30.

17.

Protons and Hydroxide Ions in Aqueous Systems.

Agmon N, Bakker HJ, Campen RK, Henchman RH, Pohl P, Roke S, Thämer M, Hassanali A.

Chem Rev. 2016 Jul 13;116(13):7642-72. doi: 10.1021/acs.chemrev.5b00736. Epub 2016 Jun 17. Review.

PMID:
27314430
18.

Reduced Cardiovascular Mortality Associated with Early Vascular Access Placement in Elderly Patients with Chronic Kidney Disease.

Lee T, Thamer M, Zhang Q, Zhang Y, Allon M.

Am J Nephrol. 2016;43(5):334-40. doi: 10.1159/000446159. Epub 2016 May 11.

19.

Ultrafast 2D IR spectroscopy of the excess proton in liquid water.

Thämer M, De Marco L, Ramasesha K, Mandal A, Tokmakoff A.

Science. 2015 Oct 2;350(6256):78-82. doi: 10.1126/science.aab3908.

20.

Predicting Early Death Among Elderly Dialysis Patients: Development and Validation of a Risk Score to Assist Shared Decision Making for Dialysis Initiation.

Thamer M, Kaufman JS, Zhang Y, Zhang Q, Cotter DJ, Bang H.

Am J Kidney Dis. 2015 Dec;66(6):1024-32. doi: 10.1053/j.ajkd.2015.05.014. Epub 2015 Jun 26.

21.

Plasmons in supported size-selected silver nanoclusters.

Lünskens T, Heister P, Thämer M, Walenta CA, Kartouzian A, Heiz U.

Phys Chem Chem Phys. 2015 Jul 21;17(27):17541-4. doi: 10.1039/c5cp01582k.

PMID:
26037213
22.

Outcomes of Elderly Patients after Predialysis Vascular Access Creation.

Lee T, Thamer M, Zhang Y, Zhang Q, Allon M.

J Am Soc Nephrol. 2015 Dec;26(12):3133-40. doi: 10.1681/ASN.2014090938. Epub 2015 Apr 8.

23.

Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.

Thamer M, Zhang Y, Kaufman J, Kshirsagar O, Cotter D, Hernán MA.

Am J Nephrol. 2014;40(6):554-60. doi: 10.1159/000370334. Epub 2015 Jan 10.

24.

Direct observation of intermolecular interactions mediated by hydrogen bonding.

De Marco L, Thämer M, Reppert M, Tokmakoff A.

J Chem Phys. 2014 Jul 21;141(3):034502. doi: 10.1063/1.4885145.

PMID:
25053321
25.

Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database.

Thamer M, Zhang Y, Kshirsagar O, Cotter DJ, Kaufman JS.

Am J Kidney Dis. 2014 Nov;64(5):706-13. doi: 10.1053/j.ajkd.2014.05.013. Epub 2014 Jul 8.

26.

Dialysis chains and placement on the waiting list for a cadaveric kidney transplant.

Zhang Y, Thamer M, Kshirsagar O, Cotter DJ, Schlesinger MJ.

Transplantation. 2014 Sep 15;98(5):543-51. doi: 10.1097/TP.0000000000000106.

PMID:
24798304
27.

Orientational changes of supported chiral 2,2'-dihydroxy-1,1'binaphthyl molecules.

Heister P, Lünskens T, Thämer M, Kartouzian A, Gerlach S, Verbiest T, Heiz U.

Phys Chem Chem Phys. 2014 Apr 28;16(16):7299-306. doi: 10.1039/c4cp00106k.

PMID:
24618806
28.

Small supported plasmonic silver clusters.

Thämer M, Kartouzian A, Heister P, Lünskens T, Gerlach S, Heiz U.

Small. 2014 Jun 25;10(12):2340-4. doi: 10.1002/smll.201303158. Epub 2014 Mar 10. No abstract available.

PMID:
24616377
29.

Comparative effectiveness of two anemia management strategies for complex elderly dialysis patients.

Zhang Y, Thamer M, Kaufman J, Cotter D, Hernán MA.

Med Care. 2014 Mar;52 Suppl 3:S132-9. doi: 10.1097/MLR.0b013e3182a53ca8.

30.

Similar Outcomes for Two Anemia Treatment Strategies among Elderly Hemodialysis Patients with Diabetes.

Thamer M, Zhang Y, Kaufman J, Cotter D, Hernán MA.

J Endocrinol Diabetes. 2014;1(2). doi: 10.15226/2374-6890/1/2/00111.

31.

Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series.

Thamer M, Zhang Y, Lai D, Kshirsagar O, Cotter D.

BMC Nephrol. 2013 Aug 9;14:172. doi: 10.1186/1471-2369-14-172.

32.

Organizational status of dialysis facilities and patient outcome: does higher injectable medication use mediate increased mortality?

Zhang Y, Thamer M, Kshirsagar O, Cotter DJ.

Health Serv Res. 2013 Jun;48(3):949-71. doi: 10.1111/1475-6773.12019. Epub 2012 Dec 6.

33.

Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.

Wicklein D, Ramos Leal N, Salamon J, Thamer M, Herrmann H, Valent P, Schumacher U, Ullrich S.

PLoS One. 2012;7(2):e30567. doi: 10.1371/journal.pone.0030567. Epub 2012 Feb 14.

34.

Quality of life, depression, and anxiety 6 months after inpatient withdrawal in patients with medication overuse headache: an observational study.

Zebenholzer K, Thamer M, Wöber C.

Clin J Pain. 2012 May;28(4):284-90. doi: 10.1097/AJP.0b013e3182321d35.

PMID:
22001669
35.

The possible effects of CMS's 'non-decision' on a national coverage decision for ESA therapy.

Cotter D, Thamer M, Zhang Y.

Nephrol News Issues. 2011 Aug;25(9):15-6, 18. No abstract available.

PMID:
21905526
36.

High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes.

Zhang Y, Thamer M, Kaufman JS, Cotter DJ, Hernán MA.

Kidney Int. 2011 Sep;80(6):663-9. doi: 10.1038/ki.2011.188. Epub 2011 Jun 22.

37.

The effect of dialysis chains on mortality among patients receiving hemodialysis.

Zhang Y, Cotter DJ, Thamer M.

Health Serv Res. 2011 Jun;46(3):747-67. doi: 10.1111/j.1475-6773.2010.01219.x. Epub 2010 Dec 9.

38.

Anemia management and mortality risk in incident hemodialysis patients.

Zhang Y, Thamer M, Cotter D.

JAMA. 2010 Jul 7;304(1):41; author reply 42-3. doi: 10.1001/jama.2010.889. No abstract available.

PMID:
20606146
39.

Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States.

Zhang Y, Thamer M, Cotter D, Kaufman J, Hernán MA.

Clin J Am Soc Nephrol. 2009 Mar;4(3):638-44. doi: 10.2215/CJN.05071008. Epub 2009 Mar 4.

40.

Prednisone, lupus activity, and permanent organ damage.

Thamer M, Hernán MA, Zhang Y, Cotter D, Petri M.

J Rheumatol. 2009 Mar;36(3):560-4. doi: 10.3899/jrheum.080828. Epub 2009 Feb 4.

41.

Relative mortality and epoetin alpha dose in hemodialysis patients.

Cotter DJ, Thamer M, Zhang Y.

Am J Kidney Dis. 2008 May;51(5):865; author reply 865-6. doi: 10.1053/j.ajkd.2007.12.045. No abstract available.

PMID:
18436099
42.

The effect of epoetin dose on hematocrit.

Cotter D, Zhang Y, Thamer M, Kaufman J, Hernán MA.

Kidney Int. 2008 Feb;73(3):347-53. Epub 2007 Nov 14.

43.

Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis: the authors respond.

Thamer M, Zhang Y, Kaufman J, Cotter D, Hernán MA.

Am J Kidney Dis. 2007 Oct;50(4):538-41. No abstract available.

PMID:
17900452
44.

Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.

Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernán MA.

JAMA. 2007 Apr 18;297(15):1667-74.

PMID:
17440144
45.

Translating epoetin research into practice: the role of government and the use of scientific evidence.

Cotter D, Thamer M, Narasimhan K, Zhang Y, Bullock K.

Health Aff (Millwood). 2006 Sep-Oct;25(5):1249-59.

PMID:
16966720
46.

Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States.

Thamer M, Zhang Y, Kaufman J, Stefanik K, Cotter DJ.

Am J Kidney Dis. 2006 Jul;48(1):77-87.

PMID:
16797389
47.

Time to consider the role of epoetin.

Zhang Y, Thamer M.

Kidney Int. 2006 May;69(10):1917; author reply 1917-8. No abstract available.

48.

Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients.

Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J.

J Clin Epidemiol. 2004 Oct;57(10):1086-95.

PMID:
15528060
49.

Epoetin requirements predict mortality in hemodialysis patients.

Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ.

Am J Kidney Dis. 2004 Nov;44(5):866-76.

PMID:
15492953
50.

Are associational studies obfuscating?

Thamer M.

Kidney Int. 2004 Jul;66(1):462; author reply 462-3. No abstract available.

Supplemental Content

Loading ...
Support Center